0022-3565/01/2983-1269 1279$3.

00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics JPET 298:12691279, 2001

Vol. 298, No. 3 3666/926394 Printed in U.S.A.

The Antidepressant-Like Effect Induced by 1-Receptor Agonists and Neuroactive Steroids in Mice Submitted to the Forced Swimming Test
ALEXANDRE URANI, FRANCOIS J. ROMAN, VAN-LY PHAN, TSUNG-PING SU, and TANGUI MAURICE
Behavioral Neuropharmacology Group, Institut National de la Sante et de la Recherche Medicale Unite 336, Montpellier, France (A.U., V.-L.P., T.M.); Pfizer-Fresnes, Fresnes, France (A.U., F.R.); and Cellular Pathobiology Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland (T.-P.S.). Received December 14, 2000; accepted May 17, 2001 This paper is available online at http://jpet.aspetjournals.org

ABSTRACT The interaction of neuroactive steroids with the 1-receptor was investigated in Swiss mice submitted to the forced swimming test. The 1-agonists igmesine and ( )-SKF-10,047 and the steroid dehydroepiandrosterone sulfate (DHEAS) showed some antidepressant-like activity by shortening the immobility time, these effects being blocked by the 1-antagonist BD1047 or progesterone. The 1-agonist PRE-084 or pregnenolone sulfate failed to affect the immobility time. In adrenalectomized/ castrated (AdX/CX) mice, the effects of igmesine and DHEAS were significantly potentiated, and PRE-084 or pregnenolone sulfate induced significant decreases of immobility time. The augmented effects in AdX/CX were fully blocked by BD1047. The effects of the classical antidepressants, desipramine or fluoxetine, were unchanged in AdX/CX mice. The effect of

stress on the 1-receptor binding and neurosteroid levels was then examined in different brain structures, in terms of in vivo ( )-[3H]SKF-10,047 binding to 1-sites and neurosteroids levels. In the hippocampus, but not in the cortex or cerebellum, inhibition of in vivo ( )-[3H]SKF-10,047 binding was measured in parallel to the extent of progesterone levels according to the endocrine conditions. These data confirmed the antidepressant ability of 1-receptor agonists and revealed that the endogenous steroidal levels tonically interfere with the efficacy of the 1-system. It was observed that local modifications in progesterone levels are directly related to the changes of in vivo 1-binding. Such observations may be of major importance in view of the therapeutic use of selective 1-agonists in depression.

Neurosteroids, according to the denomination proposed in 1981 by Baulieu (1981) and largely followed thereafter, are steroid hormones that accumulate in the brain independently of endocrine sources and can be synthesized from sterol precursors in nervous cells. Neurosteroids include progesterone, 5 -pregnane-3 -ol-20-one (allopregnanolone), pregnenolone, dehydroepiandrosterone (DHEA), or their respective sulfate esters (pregnenolone sulfate, DHEAS). Apart from their classical genomic effects, neurosteroids modulate several neurotransmission systems, in an excitatory or inhibitory way. Pregnenolone sulfate and DHEAS act as excitatory neurosteroids, since they antagonize the activation of -aminobutyric acid type A (GABAA) receptors (Majewska and Schwartz, 1987; Majewska et al., 1988), whereas they potentiate the activation of the N-methyl-D-aspartate-type of glutamatergic receptors (Wu et al., 1991; Irwin et al., 1992, 1994; Maione et al., 1992; Bowlby, 1993). Some other neuro-

This work was supported by Pfizer-Fresnes (France).

steroids, including progesterone or allopregnanolone, act as inhibitory neurosteroids, being very potent agonists of GABAA receptors (Smith, 1991). As a consequence, neuro steroids are involved in several physiopathological events, such as response to stress, depression, anxiety, sleep, epilepsy, and memory formation (for reviews, see Schumacher et al., 1997; Maurice et al., 1999). Actually, the importance of neurosteroids in depression has been shown in several clinical studies. The concentration of allopregnanolone and pregnenolone in the cerebrospinal fluid of patients with major depression was lower than in control subjects (George et al., 1994; Uzunova et al., 1998). Mood-disordered subjects, who were clinically depressed, had lower cerebrospinal fluid pregnenolone as compared with healthy volunteers (George et al., 1994). It has been shown that treatment with antidepressant corrected the unbalance of neuroactive steroids observed in depressive patients (Romeo et al., 1998). One study has already reported a benefic effect of neurosteroids as antidepressant: patients with major depression and low basal

ABBREVIATIONS: DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; GABAA, -aminobutyric acid type A receptor; AdX/CX, adrenalectomized/castrated mice; PRE-084, 2-(4-morpholinoethyl)-1-phenylcyclohexane-1-carboxylate hydrochloride; BD1047, N-[2(3,4-dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine. 1269

1270

Urani et al.

plasma DHEA were openly administered DHEA, and depression ratings significantly improved during the time of the treatment (Wolkowitz et al., 1997). A double blind clinical study recently confirmed these data (Wolkowitz et al., 1999). The 1-receptor represents a unique binding site in the central nervous system and peripheral organs, distinct from any other known transmitter receptor. The 1-receptor ligands exert a potent neuromodulation on excitatory neurotransmitter systems, including the noradrenergic, glutamatergic, and cholinergic systems (Matsuno et al., 1993; Bergeron et al., 1995; Gonzalez-Alvear and Werling, 1995a,b; Monnet et al., 1996). At the behavioral level, selective 1receptor ligands are involved in several responses, including antipsychotic activity, response to stress and depression, mechanism of sensitization to abused drugs (Ujike et al., 1992; McCracken et al., 1999; Romieu et al., 2000), and marked antiamnesic properties against several models of amnesia (for reviews, see Maurice and Lockhart, 1997; Maurice et al., 1999). The noradrenergic and glutamatergic neurotransmissions play an important role in behavioral despair (Bunney and Davis, 1965; Trullas and Skolnick, 1990). Consequently, the 1-receptor ligands present effective antidepressant effects in several animal models. The selective 1receptor agonists ( )-pentazocine, ( )-SKF-10,047, or SA4503 reduced the immobility time in the forced swimming test (Matsuno et al., 1996) and in the tail suspension test (Ukai et al., 1998). OPC-14523 also showed an antidepressant-like effect in the forced swimming test (Tottori et al., 1997). The selective 1-receptor antagonist NE-100 reversed the drug-induced reduction of immobility. Igmesine also exhibited a marked antidepressant-like effect in the rat forced swimming test and in the mouse tail suspension test (Kinsora et al., 1998), and has been tested in a clinical trials in humans with promising results (Pande et al., 1998). The interaction between neuroactive steroids and the 1receptor have been uncovered in binding studies (Su et al., 1988; Yamada et al., 1994; Maurice et al., 1996), then reported in physiological studies regarding several neuronal responses (Monnet et al., 1995; Debonnel et al., 1996), with major consequences in several models of amnesia (Maurice et al., 1997, 1998, 1999; Urani et al., 1998). It appeared from these studies that DHEA, pregnenolone, or their sulfate esters behave as 1-receptor agonists, whereas progesterone behaves as a potent antagonist. Allopregnanolone does not interact with the 1-receptor. In the forced swimming test, Reddy et al. (1998) showed that the reduction of immobility induced by DHEAS or pregnenolone sulfate was reversed by the 1-selective antagonist NE-100. Similar results were observed in a conditioned fear stress model (Noda et al., 2000). In this study, we characterized the antidepressant-like effect of several selective 1-receptor agonists and the neuroactive steroids that act as 1-receptor agonists (DHEAS or pregnenolone sulfate) using the forced swimming test in the Swiss mice. We report, through endocrine manipulations adrenalectomy/castration and inhibition of the 3 -hydroxysteroid dehydrogenase that converts pregnenolone into progesterone or of the 5 -reductase that metabolizes progesterone into 3 -pregnane-3,20-dionethat the endogenous steroidal levels play a major influence on the 1-receptor availability and behavioral effect. In addition, a biochemical study examined the effect of swimming stress on the 1-receptor/neurosteroidal systems, through in vivo and in

vitro ( )-[3H]SKF-10,047 binding to 1-sites and measurement of the neurosteroid contents in different brain structures of mice according to the different endocrine manipulations.

Materials and Methods

Animals. Male Swiss OF1 mice (Breeding Center of the Faculty of Pharmacy, Montpellier, France), aged 5 to 6 weeks and weighing 30 2 g, were used throughout the study. Animals were housed in groups in plastic cages. They had free access to laboratory chow and water, except during behavioral experiments, and they were kept in a regulated environment (23 1C, 40 60% humidity) under a 12-h light/dark cycle (light on at 7:00 AM). Experiments were carried out between 9:00 AM and 6:00 PM, in a soundproof and air-regulated experimental room, to which mice were habituated at least 30 min before each experiment. All animal procedures were conducted in strict adherence to the European Community Council Directives of November 24, 1986 (86-609/EEC) and the Decree of October 20, 1987 (87-848). Drugs. ( )-N-Cyclopropylmethyl-N-methyl-1,4-diphenyl-1-ethylbut-3-en-1-ylamine hydrochloride (igmesine, CI-1019, JO-1784) was synthesized at Pfizer, Fresnes. Finasteride, desipramine, and progesterone (4-pregnene-3,20-dione) were purchased from Sigma (St. Quentin Fallavier, France). Fluoxetine, pregnenolone sulfate (5pregnen-3 -ol-20-one sulfate), DHEAS (5-androsten-3 -ol-17-one sulfate), and ( )-SKF-10,047 were from Sigma/RBI (Natick, MA). 2-(4-Morpholinoethyl)-1-phenylcyclohexane-1-carboxylate hydrochloride (PRE-084) was provided by Dr. D.W. Parish (SRI International, Menlo Park, CA) and N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine (BD1047) by Dr. Wayne D. Bowen (National Institute of Diabetes and Digestive and Kidney Diseases/ National Institutes of Health, Bethesda, MD). Trilostane was a generous gift from Dr. G. Margetts (Stegram Pharmaceuticals, Billinghurst, UK). ( )-[3H]SKF-10,047 (1820 GBq/mmol, 37 MBq/ml), [1,2,6,7-3H(N)]progesterone (3589 GBq/mmol, 37 MBq/ml), [7-3H(N)]pregnenolone ([3H]pregnenolone, 777 GBq/mmol, 37 MBq/ ml), and [1,2,6,7-3H(N)]dehydroepiandrosterone (2220 GBq/mmol, 37 MBq/ml) and [7-3H(N)]dehydroepiandrosterone sulfate (592 GBq/ mmol, 37 MBq/ml) were from PerkinElmer Life Science Products (Boston, MA). The pregnenolone antibody was from AbCys (Paris, France), and progesterone and DHEA antibodies were from Biovalley (Marne-la-Vallee, France). Progesterone and finasteride were suspended in sesame oil; other drugs were solubilized in distilled water or saline solution. Drugs were injected subcutaneously (s.c.) or intraperitoneally (i.p.), in a volume of 100 l/20 g of body weight. Forced Swimming Test. Each mouse was placed individually in a glass cylinder (diameter 12 cm, height 24 cm) filled with water at a height of 12 cm. Water temperature was maintained at 2223C. The animal was forced to swim for 15 min on the 1st day. Animals were then allowed to return to their home cage. On the 2nd day, each mouse was placed again into the water and forced to swim for 6 min. The session was videotaped and the duration of immobility during the last 5 min was measured. The mouse was considered as immobile when it stopped struggling and moved only to remain floating in the water, keeping its head above water. Drugs were administered 30 min before the session on the 2nd day. Finasteride was administered twice, 14 and 2 h before the session on day 2. Adrenalectomy/Castration. About 1 week after habituation to the animal facilities, animals were anesthetized with sodium pentobarbital 2%, 100 l/30 g of body weight i.p. Both adrenal glands were removed, through incisions in the back of the animal, just below the breast ribs. The skin was sutured. Then, both testes were ligatured and cut through an incision in the scrotum. Animals received an injection of gentamicin 10 mg/kg i.p. and recovered within a few hours from surgery. After surgery, drinking tap water was replaced by a saccharose 1%, NaCl 0.9% solution. Animals were used for behavioral experiments 6 days after surgery.

Neurosteroids/ In Vivo ( )-[3H]SKF-10,047 Binding Assays. Mice were injected in a tail vein with 150 kBq of ( )-[3H]SKF-10,047 and sacrificed 30 min later by decapitation. The hippocampi, cortex, and cerebellum were dissected out on ice, homogenized in a 5 mM TrisHCl buffer, pH 7.4, at 4C. Two 1-ml aliquots were filtered under vacuum through GF/C filters, presoaked in 0.05% polyethylenimine (Sigma, St. Louis, MO). Total radioactivity was determined by counting 200- l aliquots of the homogenates. Preliminary experiments showed that the nonspecific binding, defined as the binding levels measured after the preadministration of haloperidol, 2 mg/kg i.p., 10 min before the tracer, represents between 5 to 9% of the total binding (Maurice et al., 1996; Phan et al., 1999). Therefore, results were expressed as total binding and calculated as bound to free radioactivity ratios (Maurice et al., 1996; Phan et al., 1999). In Vitro ( )-[3H]SKF-10,047 Binding. Control or AdX/CX animals, nonstressed or submitted to the forced swimming test 30 min before, were sacrificed by decapitation. The hippocampi were dissected out at 4C, pooled, and homogenized in 25 volumes of 50 mM Tris/HCl buffer, pH 7.4, using a Polytron homogenizer for 20 s. The homogenate was centrifuged for 15 min at 45,000g at 4C. The pellet was resuspended in 5 mM Tris/HCl buffer, pH 7.4. The homogenate was centrifuged again for 15 min at 45,000g at 4C and the pellet resuspended in the same buffer at a final concentration of 2 mg of protein/ml. Various concentrations of ( )-[3H]SKF-10,047, ranging from 1 nM to 1 M, were incubated in a total volume of 2 ml of 5 mM Tris/HCl buffer for 60 min at 25C. The bound radioactivity in 500- l aliquots was separated by filtration through Whatman GF/C filters presoaked with 0.05% polyethylenimine. The total radioactivity was determined by counting 100- l aliquots of the homogenates. The nonspecific binding levels were determined using NE-100 (100 M). The protein concentration in the homogenates was determined using bovine serum albumin (Sigma) as standard (Bradford, 1976). Extraction and Purification of Neurosteroids. Mice were sacrificed by decapitation, and the brains were quickly removed, dissected, and pooled to obtain approximately 500 mg of tissue. Samples were frozen immediately in dry ice until analysis. The samples were then weighed and homogenized in ice-cold 10 mM phosphate-buffered saline, pH 7.4. Recovery tracers ([3H]progesterone, [3H]pregnenolone, [3H]DHEA, [3H]DHEAS, 50 Bq each) were added. Then, 10 ml of ethyl acetate/isooctane, 1:1 v/v, was added and the tubes were vigorously stirred for 8 min. After centrifugation at 4,000g for 5 min, the organic phase was removed and the extraction step was repeated twice. This organic phase was then defatted with a MeOH 90%/ isooctane separation. The aqueous extracts containing unconjugated steroids were further purified by reverse-phase chromatography on Amprep C18 cartridges (Amersham, Les Ulis, France). The isooctane phases containing lipoidal derivatives were thrown away. Sulfate esters were solvolyzed. The aqueous phase from the first separation was brought to pH 1.0 with a few drops of sulfuric acid and to a NaCl concentration of 20% by adding 2:1 v/v of a 30% NaCl solution. Extraction with ethyl acetate was again performed as described above, and this extract, which contained steroid sulfates, was solvolyzed at 37C for 16 h. Ethyl acetate extracts were washed once with 1 N NaOH (0.25 volume) and twice with water (0.25 volume). The extracts were taken to dryness. The different steroids were separated using partition chromatography on celite545 (Prolabo, Fontenay-sous-Bois, France) columns, with propanediol, 1 g, as the stationary phase. Impregnated celite was settled in 5-ml disposable glass pipettes. Extracts were taken up in 1 ml of isooctane saturated with propanediol and deposited onto the columns. Progesterone was eluted with 19 ml of isooctane, pregnenolone with 15 ml of isooctane/benzene (7:3 v/v), and DHEA with 20 ml of isooctane/benzene (1:1 v/v). The recovery of the different steroids added as tracers was routinely 60 to 80%. Extraction and Purification of Plasma Steroids. Mice were anesthetized with pentobarbital 2%, and blood was collected through transcardiac punction in heparinized tubes. Samples were centrifuged 10 min at 4,000g and pooled to obtain 2 ml of plasma. Then, 3

-Receptor Interaction in Forced Swim Test

1271

ml of phosphate-buffered saline were added, and extraction/purification of steroids was performed as described. Radioimmunoassays. After separation, each steroid was quantified by radioimmunoassay using specific antibodies presenting minimal cross-reactions. Measurements were performed in triplicate of four dilutions of each purified sample. Results are expressed as nanograms per milliliter of plasma or nanograms per gram of tissue. Statistical Analysis. Results are expressed as means S.E.M. Data were analyzed using the Dunnetts multiple comparisons test after analysis of variance (F values). For the neurosteroid measurement, statistical comparison of the data was made using the Welchs test. The criteria for statistical significance were P 0.05, P 0.01, and P 0.001.

Results
Effects of 1-Receptor Agonists on the Immobility Time in the Forced Swimming Test. When submitted to forced swimming, Swiss mice rapidly developed a marked behavioral despair, showing an immobility time of 180 4 s (n 18) on the 1st day (recorded between the 2nd and 6th minute of swimming), which significantly increased up to 227 5 s on the 2nd day (t 7.92, P 0.01, paired t test). Consequently, drugs were administered before the session on day 2. The selective 1-receptor agonist igmesine significantly shortened the immobility time at the dose of 60 mg/kg i.p. [F(4,75) 4.43, P 0.01; Fig. 1A]. Similarly, the reference 1-receptor agonist ( )-SKF-10,047 decreased the immobility time, at the dose of 30 mg/kg [F(4,40) 7.72, P 0.01; Fig. 1B]. However, the other selective 1-receptor agonist PRE084 failed to affect the immobility time in the 10 to 60 mg/kg dose range [F(4,47) 0.75, P 0.05; Fig. 1C]. Lower doses were also tested (15 mg/kg) that appeared ineffective. The selective 1-receptor antagonist BD1047, tested in the 0.3 to 3 mg/kg i.p. dose range, did not affect the immobility time by itself [F(3,32) 1.70, P 0.05; Fig. 1D]. However, preadministration of BD1047, at 3 mg/kg, completely antagonized the reduction of immobility time induced by igmesine [F(4,49) 33.02, P 0.001; Fig. 1E], confirming that the drug acted through the involvement of the 1-receptor. Effects of Neuroactive Steroids on the Immobility Time in the Forced Swimming Test. DHEAS, administered in the 5 to 60 mg/kg dose range, slightly but significantly shortened the immobility time, at the 10 mg/kg dose [F(5,89) 2.80, P 0.05; Fig. 2A]. At lower or higher dosages, the steroid was devoid of effect. Pregnenolone sulfate failed to affect the immobility time in the 5 to 40 mg/kg dose range [F(4,74) 1.74, P 0.05; Fig. 2B]. Progesterone did not affect the immobility time by itself in the 5 to 60 mg/kg dose range [F(5,68) 0.21, P 0.05; Fig. 2C]. However, the preadministration of progesterone (20 60 mg/kg) before DHEAS (10 mg/kg) led to a significant antagonism of its effect, as shown in Fig. 2D [F(3,55) 6.46, P 0.001]. Interestingly, a crossed pharmacology was observed between the effects induced by the 1-receptor ligands and the steroids. First, the preadministration of progesterone fully blocked the igmesine-induced reduction of immobility [F(6,75) 15.75, P 0.001; Fig. 3A]. Second, the selective 1-receptor antagonist BD1047 also prevented the DHEAS-induced diminution of immobility time [F(4,49) 12.18, P 0.001; Fig. 3B]. Effects of 1-Receptor Ligands on the Immobility Time in the Forced Swimming Test in AdX/CX Animals. AdX/CX animals showed an immobility time of 178

1272

Urani et al.

Fig. 1. Antidepressant-like effect of 1-receptor ligands in the forced swimming test in Swiss mice: dose-response effect of igmesine (A), ( )-SKF 10,047 (B), PRE-084 (C), BD1047 (D), and antagonism by BD1047 of the igmesine-induced effect (E). Drugs were injected i.p. 30 min before the session on day 2. BD1047 was administered i.p. 15 min before igmesine, which was given 30 min before the session on day 2. The duration of immobility was recorded for the last 5 min over a 6-min session. Values are expressed as mean S.E.M. of the number of animals indicated inside each column. *P 0.05, **P 0.01 versus the vehicle-treated group (Veh); ##P 0.01 versus the igmesine-treated group (Dunnetts test).

Fig. 2. Antidepressant-like effect of neuroactive steroids in the forced swimming test in Swiss mice: dose-response effect of DHEAS (A), pregnenolone sulfate (B), progesterone (C), and antagonism by progesterone of the DHEAS-induced effect (D). The steroids were injected i.p. 30 min before the session on day 2. Progesterone was administered i.p. 15 min before DHEAS, which was given 30 min before the test. Values are expressed as mean S.E.M. of the number of animals indicated inside each column. *P 0.05, **P 0.01 versus the vehicle-treated group (Veh); ##P 0.01 versus the igmesine-treated group (Dunnetts test).

12 s (n 12) on the 1st day, which significantly increased up to 242 5 s on the 2nd day (t 4.26, P 0.01, paired t test). These values did not differ from the values measured in control animals (P 0.05 on each day). Igmesine shortened significantly the immobility time in AdX/CX animals, in a dose-dependent manner at 20 and 60 mg/kg [F(5,49) 18.70, P 0.001; Fig. 4A], thus in a more effective manner as compared with nonoperated animals (Fig. 1A). The finasteride pretreatment, which led to an increase in the endogenous levels of progesterone, did not affect the immobility time exhibited by vehicle-treated AdX/CX mice, but significantly altered the diminution induced by igmesine, at 60 mg/kg (Fig. 4A). PRE-084 allowed a significant and dose-dependent decrease of immobility time in AdX/CX animals, at 20 and 60 mg/kg [F(5,58) 6.16, P 0.001; Fig. 4B]. In the same dose range, the compound was without effect in control animals

(Fig. 1C). The finasteride pretreatment significantly affected the effect-induced PRE-084, 60 mg/kg, in AdX/CX animals (Fig. 4B). The effects induced by classical antidepressant drugs desipramine and fluoxetine failed to be affected by the suppression of circulating steroids (Fig. 5). Both drugs showed similar dose-response effects in control and AdX/CX animals, with significant reductions of the immobility time at the 30 and 60 mg/kg doses [desipramine: F(4,47) 17.76, P 0.001 in control animals, Fig. 5A; F(4,38) 19.36, P 0.001 in AdX/CX, Fig. 5B; fluoxetine: F(4,39) 8.00, P 0.001 in control animals, Fig. 5C; F(4,42) 29.76, P 0.001 in AdX/ CX; Fig. 5D]. In addition, a complementary experiment showed that the preadministration of progesterone failed to affect the reduction of immobility induced by desipramine. Immobility time was 155 12 s (n 13) for animals treated

Neurosteroids/

-Receptor Interaction in Forced Swim Test

1273

Fig. 3. Antagonism of the antidepressant-like effects of igmesine by progesterone (PROG) (A) and of DHEAS by BD1047 (B) in Swiss mice. Progesterone or BD1047 was administered i.p. 15 min before igmesine or DHEAS, respectively, which was given 30 min before the test. Values are expressed as mean S.E.M. of the number of animals indicated inside each column. *P 0.05, **P 0.01 versus the vehicle-treated group (Veh); ##P 0.01 versus the igmesine- or DHEAS-treated group (Dunnetts test).

with desipramine (30 mg/kg ip) and 162 16 s (n 12, P 0.05) for animals treated with desipramine and progesterone (40 mg/kg ip). Effects of Neuroactive Steroids on the Immobility Time in the Forced Swimming Test in AdX/CX Animals. In AdX/CX animals, both DHEAS and pregnenolone sulfate significantly shortened the immobility time, as shown in Fig. 6. The DHEAS treatment led to significant diminution of the immobility time at all the doses examined, within the 5 to 60 mg/kg dose range [F(5,56) 10.86, P 0.001; Fig. 6A], thus in a more efficient manner as compared with nonoperated animals (Fig. 2A). The pregnenolone sulfate treatment led to significant reductions of the immobility time at doses of 20 and 40 mg/kg [F(4,30) 3.24, P 0.05; Fig. 6B]. In the same dose range, the steroid was without effect in control animals (Fig. 2B). The facilitation of the effect observed in AdX/CX mice could be clearly linked to a facilitation of the 1-receptor-mediated effect, as confirmed using a pretreatment with BD1047. The antagonist fully antagonized both the antidepressant-like effect of igmesine [F(3,42) 79.61, P 0.001; Fig. 6C] and DHEAS [F(3,44) 19.16, P 0.001; Fig. 6D] in AdX/CX mice. In Vivo ( )-[3H]SKF-10,047 Binding Measures after Swimming Stress. The availability of the 1-receptor after stress and following different endocrine manipulations was examined in brain structures selected for: i) their involvement in the response to stress, ii) their role in mediating the cognitive effects of 1-agonists, and iii) the possibility to measure the neurosteroid levels using the extraction/purification/radioimmunoassay technique, i.e., the hippocampi and cortex, plus a control structure, the cerebellum. In control animals submitted to a swimming stress (Fig. 7), a significant reduction of the in vivo ( )-[3H]SKF-10,047 binding level was observed in the hippocampus [F(4,22) 5.74, P 0.001; Fig. 7A]. The inhibition was observed immediately after the stress and at the 30-min timepoint, when a 27% reduction was measured. No change was observed in the cortex [F(4,22) 1.01, P 0.05; Fig. 7B] and cerebellum [F(4,22) 0.10, P 0.05; Fig. 7C]. The immobility duration was checked and did not differ among experimental groups

Fig. 4. Antidepressant-like effect of igmesine (A) and PRE-084 (B) in the forced swimming test in AdX/CX Swiss mice. Surgery was performed 7 days before the test. Half of experimental groups were treated with finasteride (25 mg/kg s.c.) 14 and 2 h before the session on day 2. The 1-ligands were injected i.p. 30 min before the session. Values are expressed as mean S.E.M. of the number of animals indicated inside each column. **P 0.01 versus the vehicle-treated (Veh) group; ##P 0.01 versus the igmesine- or PRE-084-treated group (Dunnetts test).

[F(3,19) 1.41, P 0.05; Fig. 7D]. In AdX/CX animals submitted to a swimming stress, the in vivo ( )-[3H]SKF-10,047 binding level significantly decreased in the hippocampus [F(4,23) 5.62, P 0.001; Fig. 8A]. The inhibition was observed immediately after stress and remained significant until the 60-min timepoint. At 30 min after swimming stress, a 48% reduction was measured. No change was observed in the cortex [F(4,23) 1.08, P 0.05; Fig. 8B] and cerebellum [F(4,23) 0.44, P 0.05; Fig. 8C]. In addition, the immobility duration did not differ among experimental groups, in the 231 to 266 s range [F(3,19) 2.30, P 0.05; data not shown]. Finally, AdX/CX animals were treated twice a day with trilostane (10 mg/kg s.c.) and the in vivo ( )-[3H]SKF-10,047 binding levels measured after the swimming stress. In these conditions, no significant reduction could be observed in the hippocampus [F(4,29) 0.36, P 0.05; Fig. 8D], as well as in the cortex [F(4,29) 1.09, P 0.05; Fig. 8E] or cerebellum [F(4,28) 0.62, P 0.05; Fig. 8F]. Here, again, the immobility duration did not differ among experimental groups, in the 229 to 246 s range [F(3,19) 1.89, P 0.05; data not shown].

1274

Urani et al.

Fig. 5. Antidepressant-like effect of desipramine (A, B) and fluoxetine (C, D) in the forced swimming test in control (A, C) and AdX/CX (B, D) Swiss mice. In (B, D), surgery was performed 7 days before the test. Drugs were injected i.p. 30 min before the session on day 2. Values are expressed as mean S.E.M. of the number of animals indicated inside each column. *P 0.05, **P 0.01 versus the vehicle-treated (Veh) group (Dunnetts test).

Fig. 6. Antidepressant-like effect of DHEAS (A) and pregnenolone sulfate (B) in the forced swimming test and antagonism of the antidepressant-like effect of igmesine (C) or DHEAS (D) by BD1047 in AdX/CX Swiss mice. Surgery was performed 7 days before the test. Steroids or igmesine were injected i.p. 30 min before the session. BD1047 was administered i.p. 15 min before igmesine or DHEAS. Values are expressed as mean S.E.M. of the number of animals indicated inside each column. **P 0.05, **P 0.01 versus the vehicle-treated group (Veh); ##P 0.01 versus the igmesineor DHEAS-treated group (Dunnetts test).

In Vitro ( )-[3H]SKF-10,047 Binding Parameters after Swimming Stress. Since marked decreases of the in vivo ( )-[3H]SKF-10,047 binding levels were observed in the hippocampus of control or AdX/CX animals, the binding parameters (Kd, Bmax) were determined in saturation experiments (Table 1). Hippocampal membranes were prepared from control and/or AdX/CX animals and from animals submitted to a swimming stress 30 min before. The Scatchard analyses resulted in a single population of site with a dissociation constant, Kd value, about 6 nM and a density of sites, Bmax, about 60 fmol/mg of protein in control animals (Table 1). The stress and/or surgery failed to affect these parameters, indicating that the binding parameters of the 1-receptor are unaffected following such endocrine manipulations (Table 1).

Steroid Contents. Plasma levels of circulating progesterone were first measured to validate the endocrine manipulations (Table 2). Adrenalectomy/castration drastically decreased the progesterone levels almost under the detection limits for both nonstressed and stressed animals. In addition, the swimming stress resulted in a 2-fold increase of the progesterone levels, although not significant (Table 2). The neurosteroid measurements were limited to the steroids known to interact with the 1-receptor, namely progesterone, pregnenolone, DHEA, and their respective sulfate esters. The progesterone levels measurements in the different experimental conditions and in the different brain structures are summarized in Fig. 9. In control mice, no significant difference was observed between structures, with an average progesterone content of 3 ng/g of tissue. The swim-

Neurosteroids/

-Receptor Interaction in Forced Swim Test

1275

Fig. 7. Time course of the in vivo ( )-[3H]SKF-10,047 binding levels after a swimming stress in Swiss mice. Binding levels in the hippocampus (A), cortex (B), cerebellum (C), and immobility time of each experimental group (D). Animals were submitted to forced swimming for 15 min on day 1 and 6 min on day 2, immobility being recorded during the last 5 min. The in vivo binding assays were performed at varying intervals after swimming, the radioligand being injected 30 min before decapitation. Open circles, nonstressed control animals (n 3). The number of animals per group is indicated within the column in (D). *P 0.05, **P 0.01 versus nonstressed controls (Dunnetts test).

ming stress resulted in a significant increase of progesterone levels in the hippocampus (P 0.05; Fig. 9A). This effect was not observed in the cortex (Fig. 9B) or cerebellum (Fig. 9C), but remained significant in the whole brain (Fig. 9D). In AdX/CX mice, progesterone levels were unchanged as compared with the levels of intact animals. The progesterone level was significantly increased after stress in the hippocampus (P 0.01; Fig. 9A). This increase was greater than in intact mice: 150% versus 80%. This effect was not observed in the cortex (Fig. 9B) or cerebellum (Fig. 9C), but remained significant in the whole brain (P 0.05; Fig. 9D). The treatment with trilostane resulted in a significant decrease of progesterone levels in each structure examined and in the whole brain. In addition, stress failed to affect the progesterone levels in trilostane-treated AdX/CX mice (Fig. 9, AD). Interestingly, when increases in progesterone levels observed 30 min after stress were plotted versus the inhibition of in vivo ( )-[3H]SKF-10,047 binding measured in the hippocampus among the different endocrine conditions (intact, AdX/CX, and AdX/CX trilostane), a correlation factor of r 0.986 was measured. The measurements of the other neurosteroids led to less consistent differences, as detailed in Table 3. Basal levels of steroids varied according to the steroid and the structure examined, with average contents of 4 ng/g for pregnenolone, 6 ng/g for pregnenolone sulfate, 3 ng/g for DHEA, and 2 ng/g for DHEAS. The surgery did not affect the levels of all the neurosteroids examined. Only mild variations after stress

Fig. 8. Time course of the in vivo ( )-[3H]SKF-10,047 binding levels after a swimming stress in the hippocampus (A), cortex (B), and cerebellum (C) of AdX/CX mice, and in the hippocampus (D), cortex (E), and cerebellum (F) of AdX/CX mice treated with trilostane. Animals were submitted to forced swimming for 15 min on day 1 and 6 min on day 2, immobility being recorded for the last 5 min. The in vivo binding assays were performed at varying intervals after swimming, the radioligand being injected 30 min before decapitation. Open circles, nonstressed animals. The number of animals per group was n 5 to 9. *P 0.05, **P 0.01 versus nonstressed controls (Dunnetts test). TABLE 1 In vitro ( )-[3H]SKF-10,047 binding parameters in Swiss mouse hippocampal membrane preparations
Results are the mean S.E.M. of 3 to 4 experiments performed in triplicate. Ki nM Bmax fmol/mg protein

Intact Nonstressed Stressed AdX/CX Nonstressed Stressed

5.2 6.5 9.6 8.5 F(3,10) P

1.1 0.8 0.4 0.9 3.88 0.05

58 64 45 61 F(3,10) P

17 5 4 0 0.29 0.05

were observed. Pregnenolone levels increased in the whole brain of intact animals, and significant increases in DHEAS contents were observed in the cortex and whole brain of intact animals and in the cortex of AdX/CX animals.

Discussion
This study characterized the potential antidepressant-like effect exerted by selective 1-receptor agonists, which was previously suggested in several rodent models of behavioral despair (Matsuno et al., 1996; Tottori et al., 1997; Kinsora et al., 1998; Ukai et al., 1998). We report here that the prototypic 1-receptor agonist, ( )-SKF-10,047, as well as a more

1276

Urani et al.

TABLE 2 Plasma progesterone levels in intact or AdX/CX Swiss mice submitted to swimming stress
Values are expressed as nanograms per milliliter of plasma. Values represent mean S.E.M. from triplicate samples, each constituted from the plasma of four different mice to obtain 2 ml. AdX/CX values were close to detection limits. Progesterone Contents Nonstressed ng/ml Stressed

Intact AdX/CX
** P

0.63 0.16

0.07 0.05**

1.20 0.04

0.20 0.01**

0.01 compared to the respective intact group.

Fig. 9. Brain contents in progesterone in the hippocampus (A), cortex (B), cerebellum (C), and whole brain (D) of Swiss mice. Progesterone levels were measured in intact, AdX/CX mice, or AdX/CX mice treated for 7 days with trilostane, and levels in nonstressed ( ) or stressed (f) mice are compared. Stressed animals were sacrificed 30 min after swimming. The number of samples was n 4 to 8. *P 0.05, **P 0.01 versus nonstressed controls; #P 0.05, ##P 0.01 versus the corresponding AdX/CX group (Welchs test).

selective compound like igmesine, significantly reduced the immobility time exhibited by Swiss mice in the forced swimming test. The extent of the effect markedly varied among compounds and depending on experimental conditions. In particular, PRE-084 failed to show any effect in control animals. The selective 1-receptor antagonist BD1047 antagonized the igmesine-mediated effect, clearly demonstrating the involvement of the 1-receptor. Matsuno et al. (1996) previously reported that, in the same forced swimming test, several 1-receptor agonists, including SA4503, igmesine, and 1,3-di-o-tolylguanidine, presented potent antidepressant-like effect. Our results are in full agreement, except as concerns the active doses of the compounds. Such differences may however be attributable to the different mouse species

used in each study: ddY for Matsuno et al. (1996) and Swiss for the present study. Interestingly, the 1-receptor ligands appeared almost as effective as antidepressant drugs used in human clinical studies, such as fluoxetine or desipramine, with a only a mild shift in the active dose. Such observation confirmed the therapeutical interest for the use of selective 1-receptor agonists in depression treatment, particularly considering their lack of deleterious side effects (Matsuno and Mita, 1998). The main aspect of this study was to investigate the interaction between the 1-receptor and the neuroactive steroids in such model of depression. This interaction was first described using in vitro and in vivo binding measures of [3H]( )-SKF-10,047 to the 1-site (Su et al., 1988; Maurice et al., 1996). Progesterone appeared as the most potent inhibitor of the in vitro [3H]( )-SKF-10,047 binding in the rat brain, with a Ki value around 300 nM (Su et al., 1988). In vivo, progesterone, pregnenolone sulfate, and in a lesser extent DHEAS, decreased the [3H]( )-SKF-10,047 binding levels in the mouse brain, demonstrating the validity of this interaction in vivo (Maurice et al., 1996). Furthermore, DHEAS or pregnenolone sulfate behaved as agonists and progesterone as an antagonist in several tests assessing the 1-receptor pharmacology in vitro and in vivo (Monnet et al., 1995; Debonnel et al., 1996; Hayashi et al., 2000). In particular, the effect of DHEAS, the potentiation of N-methyl-Daspartate-evoked responses, was blocked by selective 1-receptor antagonists and progesterone blocked the 1-receptor agonist-mediated effect, as well as the steroidal effect. The effect of pregnenolone sulfate appeared much more tenuous, the steroid behaving as an agonist or inverse agonist in vitro and being ineffective in vivo (Monnet et al., 1995; Debonnel et al., 1996; Hayashi et al., 2000). A similar crossed pharmacology between the 1-receptor ligands and the neuroactive steroids was observed at the behavioral level in several amnesia models. Selective 1-receptor agonists are potent antiamnesic drugs, an effect shared by pregnenolone sulfate or DHEAS (Maurice et al., 1997, 1998; Maurice and Privat, 1997; Urani et al., 1998). Progesterone acted similarly as selective 1-receptor antagonists in these different tests. In depression models, these neuroactive steroids were previously reported to have some effect. First, DHEA alleviated behavioral despair in high-anxiety rats (Prasad et al., 1997). Second, DHEAS and pregnenolone sulfate reduced the immobility time in mice submitted to the forced swimming test. We showed here that, in control Swiss mice, DHEAS slightly but significantly reduced the immobility time, and pregnenolone sulfate was inactive. Progesterone behaved as an antagonist and blocked the DHEAS effect. The crossed pharmacology between neuroactive steroids and 1-ligands could be observed in this depression model, since progesterone blocked the effect of 1-agonists while the 1-antagonist BD1047 blocked the DHEAS effect. Moreover, progesterone affected the in vivo binding in the mouse hippocampus and cortex at doses higher than 10 mg/kg, doses relevant to the antagonist effect described in the present study. It appears therefore that the endogenous (neuro)steroidal systems interfere with the antidepressant-like effects mediated through the 1-receptor. It was however observed that in control Swiss mice, the active steroid, DHEAS, presented only a limited and bell-shaped effect in the forced swimming test. Reddy et al. (1998) reported a similar narrow dose range and

Neurosteroids/

-Receptor Interaction in Forced Swim Test

1277

TABLE 3 Central levels of pregnenolone, DHEA, and their sulfate esters in intact or AdX/CX Swiss mice submitted to swimming stress
The neurosteroids levels were measured as ng/g of tissue. Stressed animals were sacrificed 30 min after swimming. The number of samples was n Intact Neurosteroid Contents Stressed ng/g Stressed AdX/CX 4 8.

Hippocampus Pregnenolone Pregnenolone sulfate DHEA DHEA sulfate Cortex Pregnenolone Pregnenolone sulfate DHEA DHEA sulfate Cerebellum Pregnenolone Pregnenolone sulfate DHEA DHEA sulfate Whole brain Pregnenolone Pregnenolone sulfate DHEA DHEA sulfate
*P 0.05, ** P

4.61 7.62 4.11 4.39 4.11 6.84 1.81 2.45 3.85 3.61 2.20 2.22 3.70 5.10 2.86 2.59

0.84 1.14 0.10 1.36 0.54 1.39 0.39 0.60 0.86 0.72 0.60 0.51 0.70 3.07 0.62 0.55

6.13 6.62 4.71 6.75 4.01 4.58 2.14 6.27 3.30 3.2 1.96 5.40 6.27 4.52 3.43 6.19

1.02 1.96 0.55 0.40 0.85 1.56 0.38 0.61** 1.19 0.96 0.43 1.08 0.26* 0.52 0.62 0.33**

3.55 6.44 3.89 3.31 3.63 5.14 1.82 2.90 3.18 3.75 2.25 3.42 3.18 5.21 3.16 3.51

0.19 1.60 0.58 0.55 0.0.56 1.32 0.50 0.67 0.58 0.69 0.29 0.45 0.44 1.19 0.43 0.64

4.77 6.07 4.31 5.35 4.22 3.99 3.06 5.05 3.08 3.40 2.56 3.90 3.67 4.27 5.74 5.33

0.69 0.83 0.58 0.96 0.88 0.86 0.84 0.52* 0.57 0.47 0.39 0.97 1.13 0.92 1.14 1.10

0.01 vs. nonstressed controls (Welchs test).

bell-shaped effect for both DHEAS and pregnenolone sulfate, the effectiveness of steroids being observed at 5 mg/kg. In the present study, the effective dosage for DHEAS was limited to 10 mg/kg. To further investigate the relationship between the steroidal system and the 1-receptor in the forced swimming test, endocrine manipulations were carried out. Animals were adrenalectomized and castrated (AdX/CX) to remove the peripheral sources of steroids. Indeed, peripheral steroids do cross the blood-brain barrier and contaminate the brain levels of neurosteroids. Animals were then treated with finasteride, an inhibitor of the 5 -reductase enzyme that convert progesterone to 5 -pregnane-3,20-dione. This treatment led to an accumulation of neurosteroidal progesterone in the brain of AdX/CX animals (A. Urani, V. L. Phan, P. Romieu, and T. Maurice, manuscript in preparation). Furthermore, we previously reported that, in Swiss AdX/CX mice, these endocrine manipulations have major consequences on: i) the in vivo [3H]( )-SKF-10,047 binding levels in the hippocampus and cortex and ii) the extent of the antiamnesic effects of PRE-084 against the dizocilpine-induced learning deficits (Phan et al., 1999). In this study, we characterized the 1receptor-mediated antidepressant-like effect in AdX/CX animals. The fact that adrenal glands were removed is of importance using a behavioral test involving a response to stress, and it is likely that AdX/CX mice did not respond similarly to forced swimming as do control animals. However, several observations led us to consider that they performed the test in a valuable manner. In particular, the immobility duration measured for AdX/CX animals did not differ from the values measured in control animals or sham-operated ones (data not shown), during the pretest on day 1 or during the test on day 2. In addition, the maximal effects of the 1-receptor agonists were fully antagonized by BD1047 (see data herein). The effect of igmesine was enhanced in AdX/CX animals, as compared with nonoperated mice. Igmesine appeared active at 10 mg/kg, whereas in intact animals the effect appeared only at 60 mg/kg. Moreover, the surgery revealed an antidepressant-

like effect for PRE-084. The compound, which had no effect in intact animals, presented a significant effect at doses higher than 20 mg/kg in AdX/CX animals. Interestingly, however, it remained less effective than igmesine in reducing the immobility time at similar dosage, confirming that the compound may present a lower intrinsic efficacy as antidepressant, compared with igmesine. The results in AdX/CX mice suggested that circulating steroids exert a tonic modulatory effect on the 1-receptor-mediated antidepressant-like effect. The potent role of endogenous antagonist exerted by progesterone is further evidenced by the observation that the treatment with finasteride, i.e., accumulation of the neurosteroidal progesterone in the brain, blocked the 1-receptormediated effect. Interestingly, the effect of the antidepressant drugs fluoxetine and desipramine was not affected by i) progesterone preadministratrion and ii) removal of circulating steroids, clearly indicating that the mechanism of the 1-receptormediated antidepressant-like effect is different from the effect induced by classical antidepressants and does not involve an indirect inhibition of monoamine transporters. It has been suggested that fluoxetine may also act by correcting the imbalance between several neurosteroids, as observed during major depression (Romeo et al., 1998). The steroids concerned are 5 -pregnane-3 -ol-20-one, 5 -pregnane-3 -ol20-one, and 5 -pregnane-3 -ol-20-one, which are potent modulators of the GABAA receptor and do not interact with 1-receptor. The relative importance of this alternative mechanism as compared with the direct effect described in the present paper remains to be further investigated. In AdX/CX animals, the effect of the neuroactive steroids was also enhanced. The extent of the DHEAS effect was increased, and the steroid was effective at all the doses tested, although it reduced immobility only at 10 mg/kg in intact animals. Pregnenolone sulfate, which was ineffective in intact animals, had an antidepressant-like effect in AdX/CX animals, similar to what was observed with PRE084. Moreover, in AdX/CX animals, the effect of DHEAS, like

1278

Urani et al.

the effect of igmesine, was completely blocked by BD1047. Taken together, these results suggest that the limited effect induced by DHEAS in control animals and the lack of effect of pregnenolone sulfate are due to the impeding effect of endogenous progesterone. It also confirmed that the mechanism of the antidepressant-like actions of neuroactive steroids and 1-receptor agonists are closely related. The second part of the present study examined the parallel changes between the in vivo binding levels at the 1-receptor, labeled using ( )-[3H]SKF-10,047, and the contents in several neuroactive steroids, in the brain of the Swiss mouse submitted to an acute stress induced by forced swimming. In the hippocampus, the in vivo binding levels of ( )-[3H]SKF-10,047 decreased immediately after stress ( 27%), and this effect persisted significantly until 30 min after the stress. Such an effect was not observed in the other structures examined, namely the cortex and cerebellum. This effect was enhanced in AdX/CX animals, deprived of circulating steroids: 48% inhibition and longer in duration, remaining significant until 60 min after stress. However, it was completely blocked in AdX/CX animals treated with trilostane, a 3 -hydroxysteroid dehydrogenase inhibitor that blocks the formation of progesterone. In nonstressed animals, the in vivo ( )-[3H]SKF-10,047 binding levels were higher in AdX/CX animals compared with controls and furthermore in trilostane-treated animals, confirming previous observations (Phan et al., 1999). The higher levels of binding in AdX/CX animals is likely to reflect not only the decreased levels of circulating progesterone in plasma that can almost be considered as close to the detection limits after surgery (Table 2), but also the deprivation of other steroids bearing some affinity for the 1-sites, including, but not limited to, testosterone or desoxycorticosterone (Su et al., 1988). The hippocampal levels of progesterone were unchanged after surgery, but appeared highly significantly decreased after the trilostane treatment (Fig. 4), confirming that the levels of in vivo ( )[3H]SKF-10,047 binding in basal conditions are negatively correlated to the progesterone contents in the brain. The transient decrease of in vivo ( )-[3H]SKF-10,047 binding levels in the hippocampus after acute swimming stress may be related to either particular changes in the binding parameters of the 1-receptor, including reduction in apparent affinity or modification of the association or dissociation rates, or the release of endogenous neurotransmitter or hormones, including the putative but as yet unidentified endogenous ligand sigmaphin (Su et al., 1986). Modifications of the binding parameters of the 1-receptor were assessed using saturation experiments in vitro. It was clearly observed that neither the surgery nor the acute stress affected significantly the apparent affinity and the number of sites under our experimental conditions. It appeared thus that the hypothesis of a transient release of endogenous modulator, shortly after stress, might be relevant. The neurosteroidal progesterone appeared as the main candidate according to the following observations. i) Increases in progesterone appeared the most pronounced in the hippocampus, compared with the other structures examined and as observed for the changes in the in vivo ( )-[3H]SKF-10,047 binding. ii) Variations in the hippocampal progesterone content correlated closely to the inhibition of binding. iii) The changes, induced after the endocrine manipulations and acute stress, of the brain contents in the other steroids appeared unrelated to the selective inhibition of hippocampal in vivo binding to the 1-sites. Indeed, no difference was found between intact and

AdX/CX mice, in accordance with previous reports showing that adrenalectomy/castration does not affect neurosteroid content (Corpechot et al., 1981, 1983; Purdy et al., 1991). Stress induced an increase in pregnenolone level in intact animals as previously described (Barbaccia et al., 1996). Stress also induced an increase in DHEAS content in the cortex and whole brain of intact animals and in the cortex of AdX/CX animals. iv) Progesterone plays a particular role as a neuromodulatory hormone: first, as precursor of allopregnanolone and other related stressinduced steroids and second, as the steroid presenting the highest affinity for the 1-receptor (Su et al., 1988; Maurice et al., 1996) and behaving as a potent antagonist (Monnet et al., 1995; Bergeron et al., 1996; Maurice and Privat, 1997). It can thus be proposed that progesterone is released during stress, not only in periphery, but also centrally; this release exerts a blockade of the 1-receptor. The release of progesterone in response to stress appeared however as an important physiological response (Purdy et al., 1991; Duncan et al., 1998). Interestingly, it was observed that when peripheral progesterone is lacking, in AdX/CX animals, the brain is able to partly compensate by increasing the release of progesterone from neurosteroidal origin (from 80% to 150%). Selective 1-receptor agonists, when injected systemically, would compete with the high levels of progesterone to exert their pharmacological effect as antidepressants. Finally, the biochemical data confirmed the behavioral observations. The antidepressant-like effects of the 1-agonists from synthetic or steroidal origin, namely igmesine, PRE-084, DHEAS, or pregnenolone sulfate, in the forced swimming test was highly dependent on the endogenous progesterone levels following different endocrine manipulations. The effect of igmesine or DHEAS observed in intact animals was enhanced in AdX/CX animals. This result can be related to the observation that the in vivo ( )-[3H]SKF-10,047 binding level is increased, compared with intact animals. Furthermore, accumulation of progesterone using a treatment with finasteride, a 5 -reductase inhibitor that blocks the metabolism of progesterone, attenuated the efficacy of the 1-agonists. In conclusion, these results are in accordance with clinical studies showing that neurosteroids, and DHEA in particular, may be potent antidepressants (Wolkowitz et al., 1997, 1999). Moreover, we show here that the antidepressant-like effect of neuroactive steroids is mediated by a direct interaction with the 1-receptor. Our results also demonstrate that the efficacy as antidepressant critically depends on the hormonal status of the animal. An acute stress induces the release of progesterone from the peripheral and central sources, which in turn interacts transiently with the 1-receptor. This negative regulation, since progesterone behaves as a potent 1antagonist, must be overridden by the selective synthetic 1-agonists to exert their antidepressant-like effect. These observations are of clinical importance, suggesting that the (neuro)steroidal levels of patients are to be taken in account in case of antidepressant therapy involving 1-agonist. It is almost impossible at present to assess the levels of neurosteroids in vivo in patients. However, depressed patients with decreasing levels of neurosteroids, such as in the elderly, may be particularly sensitive to such therapy.
Acknowledgments

Thanks are due to Drs. D. W. Parish, W. D. Bowen, and G. Margetts for their gift of drugs. We heartily acknowledge B. Ey-

Neurosteroids/ chenne (INSERM U. 488, Le Kremlin-Bicetre, France) and Dr. C. Barberis (INSERM U. 469, Montpellier, France) for skillful advice throughout the study.
References
Barbaccia ML, Roscetti G, Bolacchi F, Concas A, Mostallino MC, Purdy RH and Biggio G (1996) Stress-induced increase in brain neuroactive steroids: antagonism by abecamil. Pharmacol Biochem Behav 54:205210. Baulieu EE (1981) Steroid hormones in the brain: several mechanisms, in Steroid Hormone Regulation of the Brain (Fuxe K, Gustafson JA and Wettenberg L eds) pp 314, Pergamon Press, Oxford. Bergeron R, de Montigny C and Debonnel G (1995) Biphasic effects of sigma ligands on the neuronal response to N-methyl-D-aspartate. Naunyn Schmiedebergs Arch Pharmacol 351:252260. Bergeron R, de Montigny C and Debonnel G (1996) Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J Neurosci 16:11931202. Bowlby MR (1993) Pregnenolone sulfate potentiation of N-methyl-D-aspartate receptor channels in hippocampal neurons. Mol Pharmacol 43:813 819. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248 254. Bunney WE and Davis JM (1965) Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry 13:483 494. Corpechot C, Robel P, Axelson M, Sjovall J and Baulieu EE (1981) Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc Natl Acad Sci USA 78:4704 4707. Corpechot C, Synguelakis M, Talha S, Axelson M, Sjovall J, Virko R, Baulieu EE and Robel P (1983) Pregnenolone and its sulfate ester in the rat brain. Brain Res 270:119 125. Debonnel G, Bergeron R and de Montigny C (1996) Potentiation by dehydroepiandrosterone of the neuronal response to N-methyl-D-aspartate in the CA3 region of the rat dorsal hippocampus: an effect mediated via (sigma) receptors. J Endocrinol 150:S33S42. Duncan GE, Knapp DJ, Carson SW and Breese GR (1998) Differential effects of chronic antidepressant treatment on swim stress- and fluoxetine-induced secretion of corticosterone and progesterone. J Pharmacol Exp Ther 285:579 587. George MS, Guidotti A, Rubinow D, Pan B, Mikalauskas K and Post RM (1994) CSF neuroactive steroids in affective disorders: pregnenolone, progesterone and DBI. Biol Psychiatry 35:775780. Gonzalez-Alvear GM and Werling LL (1995b) Sigma receptor regulation of norepinephrine release from rat hippocampal slices. Brain Res 673:61 69. Gonzalez-Alvear GM and Werling LL (1995a) 1 receptors in rat striatum regulate NMDA-stimulated [3H]dopamine release via a presynaptic mechanism. Eur J Pharmacol 294:713719. Hayashi T, Maurice T and Su TP (2000) Ca2 signaling via 1-receptors novel regulatory mechanism affecting intracellular Ca2 concentration. J Pharmacol Exp Ther 293:788 798. Irwin RP, Lin SZ, Rogawski MA, Purdy RH and Paul SM (1994) Steroid potentiation and inhibition of N-methyl-D-aspartate receptor-mediated intracellular Ca2 responses: structure-activity studies. J Pharmacol Exp Ther 271:677 682. Irwin RP, Maragakis NJ, Rogawski MA, Purdy RH, Farb DH and Paul SM (1992) Pregnenolone sulfate augments NMDA receptor mediated increases in intracellular Ca2 in cultured rat hippocampal neurons. Neurosci Lett 141:30 34. Kinsora JJ, Corbin AE, Snyder BJ, Wiley JN, Meltzer LT and Heffner TG (1998) Effects of igmesine in preclinical antidepressant tests. Soc Neurosci Abstr 24:744. Maione S, Berrino L, Vitagliano S, Leyva J and Rossi F (1992) Pregnenolone sulfate increases the convulsant potency of N-methyl-D-aspartate in mice. Eur J Pharmacol 219:477 479. Majewska MD, Mienville JM and Vicini S (1988) Neurosteroid pregnenolone sulfate antagonizes electrophysiological responses to GABA in neurons. Neurosci Lett 90:279 284. Majewska MD and Schwartz RD (1987) Pregnenolone-sulfate: an endogenous antagonist of the -aminobutyric acid receptor complex in brain? Brain Res 404:355 360. Matsuno K, Kobayashi T, Tanaka MK and Mita S (1996) 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol 312:267271. Matsuno K, Matsunaga K, Senda T and Mita S (1993) Increase in extracellular acetylcholine level by sigma ligands in rat frontal cortex. J Pharmacol Exp Ther 265:851 859. Matsuno K and Mita S (1998) SA4503: a novel 1 receptor agonist, in CNS Drug Rev (Hanin I and Scriabine A eds) pp 124, Neva Press, Branford, CT. Maurice T, Junien JL and Privat A (1997) Dehydroepiandrosterone sulfate attenuates dizocilpine-induced learning impairment in mice via 1 receptors. Behav Brain Res 83:159 164. Maurice T and Lockhart BP (1997) Neuroprotective and anti-amnesic potentials of sigma ( ) receptor ligands. Prog Neuropsychopharmacol Biol Psychiatry 21:69 102. Maurice T, Phan VL, Urani A, Kamei H, Noda Y and Naneshima T (1999) Neuroactive steroids as endogenous effectors for the sigma1 ( 1) receptor: pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol 81:125155.

-Receptor Interaction in Forced Swim Test

1279

Maurice T and Privat A (1997) SA4503, a novel cognitive enhancer with sigma1 ( 1) receptor agonist properties, facilitates NMDA receptor-dependent learning in mice. Eur J Pharmacol 328:9 18. Maurice T, Roman FJ and Privat A (1996) Modulation by neurosteroids of the in vivo ( )-[3H]SKF-10,047 binding to sigma1 receptors in the mouse forebrain. J Neurosci Res 46:734 743. Maurice T, Su TP and Privat A (1998) Sigma1 ( 1) receptor agonists and neurosteroids attenuate 2535-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience 83:413 428. McCracken KA, Bowen WD and Matsumoto RR (1999) Novel sigma receptor ligands attenuate the locomotor stimulatory effects of cocaine. Eur J Pharmacol 365:35 38. Monnet FP, de Costa BR and Bowen WD (1996) Differentiation of sigma ligandactivated receptor subtypes that modulate NMDA-evoked [3H]-noradrenaline release in rat hippocampal slices. Br J Pharmacol 119:6572. Monnet FP, Mahe V, Robel P and Baulieu EE (1995) Neurosteroids, via sigma receptors, modulate the [3H]norepinephrine release evoked by N-methyl-Daspartate in the rat hippocampus. Proc Natl Acad Sci USA 92:3774 3778. Noda Y, Kamei H, Kamei Y, Nagai T, Nishida M and Nabeshima T (2000) Neurosteroids ameliorate conditioned fear stress. An association with sigma1 receptors. Neuropsychopharmacology 23:276 284. Pande AC, Geneve J and Scherrer B (1998) Igmesine. Meeting Abstract of Collegium ` Internationale Neuro-Psychopharmacologicum, Glasgow, UK, p 30S. Phan VL, Su TP, Privat A and Maurice T (1999) Modulation of steroidal levels by adrenalectomy/castration and inhibition of neurosteroid synthesis enzymes affect 1 receptor-mediated behaviour in mice. Eur J Neurosci 11:23852396. Prasad A, Imamura M and Prasad C (1997) Dehydroepiandrosterone decreases behavioral despair in high- but not low-anxiety rats. Physiol Behav 62:10531057. Purdy RH, Morrow AL, Moore PH and Paul SM (1991) Stress-induced elevations of -aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 88:4553 4557. Reddy DS, Kaur G and Kulkarni SK (1998) Sigma ( 1) receptor mediated antidepressant-like effects of neurosteroids in the Porsolt forced swim test. Neuroreport 9:3069 3073. Romeo E, Strohle A, Spalletta G, di Michele F, Hermann B, Holsboer F, Pasini A and Rupprecht R (1998) Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 155:910 913. Romieu P, Martin-Fardon R and Maurice T (2000) Involvement of the sigma1 ( 1) receptor in the cocaine-induced conditioned place preference. Neuroreport 11: 28852888. Schumacher M, Guennoun R, Robel P and Baulieu EE (1997) Neurosteroids in the hippocampus: neuronal plasticity and memory. Stress 2:6578. Smith SS (1991) Progesterone administration attenuates excitatory amino acid responses of cerebellar Purkinje cells. Neuroscience 42:309 320. Su TP, London ED and Jaffe JH (1988) Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science (Wash DC) 240:219 221. Su TP, Weissman AD and Yer SY (1986) Endogenous ligands for sigma opioid receptors in the brain (sigmaphin): evidence from binding assays. Life Sci 38: 2199 2210. Tottori K, Kikuchi T, Uwahodo Y, Yamada S, Oshiro Y and Koga N (1997) Antidepressant effect of OPC-14523 in the forced swimming test. Jpn J Pharmacol 73:59. Trullas R and Skolnick P (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185:110. Ujike H, Kanzaki A, Okumura K, Akiyama K and Otsuki S (1992) Sigma ( ) antagonist BMY 14802 prevents methamphetamine-induced sensitization. Life Sci 50:PL129 PL134. Ukai M, Maeda H, Nanya Y, Kameyama T and Matsuno K (1998) Beneficial effects of acute and repeated administrations of receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol Biochem Behav 61:247252. Urani A, Privat A and Maurice T (1998) The modulation by neurosteroids of the scopolamine-induced learning impairment in mice involves an interaction with sigma1 ( 1) receptors. Brain Res 799:64 77. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E and Guidotti A (1998) Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 95:3239 3244. Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, Ormiston S, Johnson R, Canick J, Brizendine L and Weingartner H (1997) Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 41:311318. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L and Roberts E (1999) Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 156:646 649. Wu FS, Gibbs TT and Farb DH (1991) Pregnenolone sulfate: A positive allosteric modulator at the N-methyl-D-aspartate receptor. Mol Pharmacol 40:333336. Yamada M, Nishigami T, Nakasho K, Nishimoto Y and Miyaji H (1994) Relationship between sigma-like site and progesterone-binding site of adult male rat liver microsomes. Hepatology 20:12711280.

Address correspondence to: Dr. Tangui Maurice, Behavioral Neuropharmacology Group, INSERM U. 336, Institut de Biologie, 4, Blvd. Henri IV, 34060 Montpellier, France. E-mail: maurice@medecine.univ-montp1.fr